The following stories appear in full on today's Vidyya Medical News Service Web site.
Escitalopram, an isomer of Celexatm (citalopram HBr) and a more potent and selective serotonin reuptake inhibitor (SSRI) produced significant improvement relative to placebo at 10 mg/day and 20 mg/day doses in a Phase III clinical trial of 366 patients with major depressive disorder, reported researchers here today at the American College of Neuropsychopharmacology 2000 Annual Meeting in San Juan, Puerto Rico.
For more information: Next Generation SSRIs Successfully Complete Phase III Clinical Trial
The commencement of the tenth clinical trial of an angiogenesis inhibitor by EntreMed, Inc., in just over one year, has started. EntreMed has initiated a Phase I clinical trial of Angiostatin, a potent, naturally occurring inhibitor of angiogenesis, administered by subcutaneous, or beneath the skin, injection. To date, four cancer patients with progressive disease have already received Angiostatin through twice daily subcutaneous injections to assess the safety of this route of injection. Patients will treat themselves with Angiostatin at home.
For more information: New Approach To Cancer Chemotherapy Starts Tenth Phase I Clinical Trial
Psychemedics Corporation has received 510(K) clearance from the Food and Drug Administration (FDA) for its test for the detection of opiates in human hair. This is the first FDA clearance for a test using human hair for drugs of abuse.
For more information: First FDA Clearance For Test Using Human Hair For Drugs Of Abuse Granted
The Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH) announces the availability of the first issue of the "Annual Bibliography of Significant Advances in Dietary Supplement Research". Developed as a joint effort of ODS and the Consumer Healthcare Products Association (CHPA), this publication illustrates how the dietary supplement field is advancing through quality research. Get the document in today's issue of Vidyya.
For more information: Annual Bibliography of Significant Advances in Dietary Supplement Research 1999
A new study suggests that drinking coffee regularly might protect smokers from bladder cancer. The study found that bladder cancer was about half as likely to occur in smokers who regularly drank coffee as in smokers who did not.
For more information: Could Coffee Modify Cancer Risk?
Today's Vidyya articles are:
As always, we hope you enjoy the issue.